Horizon Pharma (HZNP) Tops Q4 EPS by 7c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Horizon Pharma plc Announces Fourth-Quarter and Full-Year 2017 Results
February 28, 2018 7:01 AM EST-- Fourth-Quarter 2017 Net Sales of $274.2 Million;Fourth-Quarter 2017 Net Loss of $46.4 Million; Adjusted EBITDA of $102.7 Million --
-- Fourth-Quarter 2017 Operating Cash Flow of $143.2 Million; Fourth-Quarter 2017 Non-GAAP Operating Cash Flow of $157.9 Million --
-- Full-Year 2017 Net Sales of $1.056 Billion; Full-Year 2017 Net Loss of $410.5 Million; Adjusted EBITDA of $389.7 Million --
-- Full-Year 2017 Operating Cash Flow of $280.2 Million; Full-Year 2017 Non-GAAP Operating Cash Flow of $393.1 Million; Year-End 2017 Cash Balance of $751.4 Million --
-- Full-Year 2017 Net Sales of Rare Disease Medicines Increased 60 Percent from Full-Year 2016 and... More
